Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu-64/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy

doi:10.1021/acs.molpharmaceut.7b00649

	Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu-64/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy
	Du, Yang1 ; Liang, Xiaolong2 ; Li, Yuan 1,3; Sun, Ting 1,3; Jin, Zhengyu 3; Xue, Huadan 3; Tian, Jie 1
发表期刊	MOLECULAR PHARMACEUTICS
	2017-11-01
卷号	14 期号:11 页码:3978-3986
文章类型	Article
摘要	The overexpression of programmed cell death-1 (PD 1) in tumors as breast cancer makes it a possible target for cancer imaging and therapy. Advances in molecular imaging, including radionuclide imaging and near-infrared fluorescence (NIRF) imaging, enable the detection of tumors with high sensitivity. In this study, we aim to develop a novel PD-1 antibody targeted positron emission tomography (PET) and NIRF labeled liposome loaded with doxorubicin (DOX) and evaluate its application for in vivo cancer imaging and therapy. IRDye800CW and Cu-60 were conjugated to liposomes with PD-1 antibody labeling, and DOX was inside the liposomes to form theranostic nanopartides. The 4T1 tumors were successfully visualized with PD-1-LiposomeDOX-Cu-64/IRDye800CW using NIRF/PET imaging. The bioluminescent imaging (BLI) results showed that tumor growth was significantly inhibited in the PD-1-Liposome-DOX-treated group than the IgG control. Our results highlight the potential of using dual-labeled theranostic PD-1 mAb-targeted Liposome-DOX-Cu-64/IRDye800CW for the management of breast tumor.
关键词	Programmed Cell Death-i (Pd-i) Near-infrared Fluorescence (Nirf) Imaging Pet Imaging Doxorubicin (Dox) Breast Cancer Therapy
WOS标题词	Science & Technology ; Life Sciences & Biomedicine
DOI	10.1021/acs.molpharmaceut.7b00649
关键词[WOS]	CELL LUNG-CANCER ; INFILTRATING LYMPHOCYTES ; ANTI-PD-L1 ANTIBODY ; DELIVERY-SYSTEMS ; POOR-PROGNOSIS ; CHEMOTHERAPY ; COMBINATION ; NIVOLUMAB ; EXPRESSION ; RESISTANCE
收录类别	SCI
语种	英语
项目资助者	National Natural Science Foundation of China(81227901 ; Research and Development Program of China (973)(2014CB748600 ; Strategic Priority Research Program from Chinese Academy of Sciences(XDB02060010) ; Beijing Natural Science Foundation(Z16110200010000) ; Peking University Third Hospital(BYSY2015023) ; 81470083 ; 2015CB755500) ; 81527805 ; 81571810 ; 61231004 ; 81771846)
WOS研究方向	Research & Experimental Medicine ; Pharmacology & Pharmacy
WOS类目	Medicine, Research & Experimental ; Pharmacology & Pharmacy
WOS记录号	WOS:000414820000034
引用统计	被引频次：55[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/19589
专题	中国科学院分子影像重点实验室
作者单位	1.Chinese Acad Sci, Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Inst Automat, Beijing 100190, Peoples R China 2.Peking Univ, Hosp 3, Dept Ultrasound, Beijing 100191, Peoples R China 3.Beijing Union Med Coll Hosp, Dept Radiol, Beijing 100006, Peoples R China
推荐引用方式 GB/T 7714	Du, Yang,Liang, Xiaolong,Li, Yuan,et al. Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu-64/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy[J]. MOLECULAR PHARMACEUTICS,2017,14(11):3978-3986.
APA	Du, Yang.,Liang, Xiaolong.,Li, Yuan.,Sun, Ting.,Jin, Zhengyu.,...&Tian, Jie.(2017).Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu-64/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy.MOLECULAR PHARMACEUTICS,14(11),3978-3986.
MLA	Du, Yang,et al."Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-Cu-64/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy".MOLECULAR PHARMACEUTICS 14.11(2017):3978-3986.

条目包含的文件		下载所有文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
Acs.molpharmaceut-du（4708KB）	期刊论文	作者接受稿	开放获取	CC BY-NC-SA	浏览下载